Rondecabtagene Autoleucel

Preferred Label : Rondecabtagene Autoleucel;

NCIt synonyms : Autologous Anti-CD19/CD20 OR-gate CAR T-cells IMPT-314; Autologous Anti-CD19/CD20 CAR T Cells IMPT-314; Autologous Anti-CD19/CD20 Bispecific CAR-T Cells IMPT-314;

NCIt definition : A preparation of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, with potential immunostimulating and antineoplastic activities. Upon administration, rondecabtagene autoleucel targets and binds to CD19- and CD20-expressing tumor B-cells. This induces selective toxicity in tumor B-cells expressing these TAAs. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting both CD19 and CD20 may prevent tumor cell antigen escape and relapse.;

UNII : YRT2H8MH4G;

Molecule name : IMPT-314; IMPT 314;

NCI Metathesaurus CUI : CL1906561;

Details

Origin ID

C199659;

UMLS CUI

C5854451;

Semantic type(s)
- Cell [UMLS semantic type]
chemical_or_drug_affects_cell_type_or_tissue
- Cytotoxic T-Lymphocyte [NCIt concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Sensitization [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Immunopotentiation [NCIt concept]
- T-Cell Activation [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- B-Lymphocyte Antigen CD19 [NCIt concept]
- B-Lymphocyte Antigen CD20 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients